Compare Neurocrine Biosciences Inc (NBIX) vs Prudential Financial Inc (PRU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Prudential Financial Inc — how do they compare? Neurocrine Biosciences Inc trades at $158.35 (market cap $16.46B), while Prudential Financial Inc trades at $122.22 (market cap $42.20B). The key difference: Prudential Financial Inc is far larger — about 2.6× Neurocrine Biosciences Inc's market cap, and Prudential Financial Inc pays a 4.58% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | PRU | |
|---|---|---|
Market Cap | $16.46B | $42.20B |
Sector | Health | Financials |
52-Week High | $185.50 | $123.93 |
52-Week Low | $123.10 | $92.00 |
Enterprise Value | $16.48B | $70.98B |
Dividend Yield | — | 4.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $158.89, down 3.66% in the past 24 hours, reflecting near-term bearish technical signals. The stock shows strong fundamentals with Q2 2026 revenue growth of 39% year-over-year to $959 million and a net income margin of 20.91%. Recent news highlights include positive clinical data for INGREZZA and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.
The outlook remains positive given robust earnings beats, raised 2026 sales guidance, and a consensus price target of $208.82 implying significant upside. Risks include clinical trial setbacks, competitive pressures, and regulatory scrutiny. Analyst sentiment is strongly bullish with 86% buy ratings, supporting a growth-oriented investment case amid near-term volatility.
Prudential Financial (PRU) trades at $122.11, up 0.68% today, with a bullish technical signal and strong Q2 2026 earnings beats. The stock shows solid fundamentals with a P/E of 11.09, ROE of 12.46%, and a $1.40 quarterly dividend. Recent news highlights strategic growth in wealth management and PGIM strength, though China tax concerns caused volatility.
Outlook is cautiously positive given earnings momentum and capital-light strategy, but risks include regulatory uncertainty in China and mixed analyst sentiment with 67.57% hold ratings. The consensus price target of $113.11 suggests limited upside from current levels, requiring monitoring of international operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →
